MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

FDA Expands Approval of GSK’s Jemperli for Endometrial Cancer Treatment

NextEdge Admin

02 Aug 2024

1 min 48 sec

Endometrial Cancer,Oncology,immune checkpoint inhibitors

GSK plc announced that the US FDA has approved Jemperli (dostarlimab) combined with carboplatin and paclitaxel chemotherapy, followed by Jemperli alone, for treating adult patients with primary advanced or recurrent endometrial cancer. This approval extends to patients with mismatch repair proficient (MMRp) and microsatellite stable (MSS) tumors, who make up 70-75% of endometrial cancer cases and have limited treatment options. The approval was based on results from the RUBY phase III trial, which demonstrated a significant improvement in overall survival (OS) and progression-free survival (PFS). Patients receiving Jemperli plus chemotherapy showed a 31% reduction in risk of death and a 16.4-month improvement in median OS compared to chemotherapy alone. The safety profile was consistent with known effects of the individual agents.

Dr. Matthew Powell highlighted the expanded approval's impact on treatment outcomes, marking a significant advancement in endometrial cancer care.

Adrienne Moore, President of ECANA, emphasized the hope this new treatment brings to patients and their families.

Jemperli, a PD-1-blocking antibody, continues to be a key component in GSK’s immuno-oncology research, with ongoing trials in various cancers aiming for transformative results.